HER2 protein: constitutive extended conformation and dimerization-driven tumor signaling mechanisms
This article focuses on the structural characteristics and signal transduction mechanisms of human epidermal growth factor receptor 2 (HER2), systematically elaborating on the family architecture through which the four HER family receptors integrate biological signals via homodimerization and heterodimerization, analyzing the structural basis by which the HER2 extracellular domain, due to its constitutively extended conformation, becomes the preferred binding partner within the family, and exploring the signaling logic by which it induces tyrosine kinase phosphorylation of the cytoplasmic domain through dimerization and activates the PI3K and MAPK pathways.
- Recent Advances
- Product Information
Recent Advances
HER2 Protein: Constitutively Extended Conformation and Dimerization-Driven Tumor Signaling Mechanisms
Summary: This article focuses on the structural features and signal transduction mechanisms of human epidermal growth factor receptor 2 (HER2), systematically describing the family architecture through which the four HER receptors integrate biological signals via homo- and heterodimerization, analyzing the structural basis by which the HER2 extracellular domain, owing to its constitutively extended conformation, becomes the preferred binding partner within the family, and discussing the signaling logic by which dimerization induces tyrosine kinase phosphorylation in the cytoplasmic domain and activates the PI3K and MAPK pathways.
I. Receptor Composition and Signal Integration Architecture of the HER Family.
The human epidermal growth factor receptor is a family of four transmembrane tyrosine kinase receptors, namely EGFR (also known as HER1), HER2, HER3, and HER4, which can dimerize with one another and mediate cell growth, differentiation, and survival. The four HER receptors form ten different homodimers and heterodimers, thereby integrating complex biological signaling events. This "four receptors, ten combinations" architecture carries important significance for signal integration: different receptor combinations differ in ligand preference, kinase activity, and downstream pathway selection, enabling a single family to respond to diverse physiological signal inputs with a limited number of molecules. Overexpression of HER2 has been shown to be associated with aggressive tumors, making it a key target for anticancer drug development. Ligand-induced homo- or heterodimerization of HER proteins initiates downstream phosphorylation signaling cascades that stimulate cell growth, proliferation, and differentiation. These four HER proteins are highly relevant to tumorigenesis, among which EGFR and HER2 are considered the most potent oncoproteins, and their overexpression is associated with multiple types of cancer, including breast cancer, lung cancer, and gastroesophageal cancer.

II. Two Conformational States of the HER Receptor Extracellular Domain.
Studies have shown that the extracellular domain of the HER receptor family consists of four subdomains and can exist in only two forms: the tethered form and the extended form. In the tethered form, owing to the interaction between subdomain II and subdomain IV, the extracellular domain cannot mediate dimerization; however, in the extended form, the dimerization elements of the receptor are fully exposed, thereby permitting dimerization and signal transduction. This "tethered–extended" binary conformational model constitutes a unified framework for understanding the regulation of HER family activation: the essential effect of ligand binding is to break the intramolecular interaction between subdomains II and IV, switching the receptor from the tethered state to the extended state and exposing the dimerization interface. Therefore, whether dimerization can occur depends on whether the extracellular domain is in the extended conformation, rather than on a simple additive effect of receptor expression levels.
III. Structural Basis and Functional Consequences of the Constitutively Extended Conformation of HER2.
What is unique about HER2 is that it exists in a constitutively extended form, which is stabilized by direct interaction between subdomains I and III. This explains both why HER2 is the preferred binding partner of other HER family members and why it is important in tumor development. This structural feature has dual functional consequences. First, HER2 presents an extended conformation without the need for ligand induction, meaning that it is always in a "ready-to-dimerize" state; therefore, when co-expressed with other HER members, HER2 becomes the highest-priority binding partner. Second, when HER2 is expressed at high density on the cell membrane owing to gene amplification, its constitutively extended conformation significantly increases the probability of homodimerization, thereby producing sustained ligand-independent signal output. From a structural logic perspective, the oncogenic potential of HER2 does not arise from a mutational "switch" effect, but rather from a shift in the dimerization equilibrium driven by the combined action of its conformational state and expression density—this is precisely the fundamental difference between HER2 and EGFR, which requires ligand-induced activation.
IV. Activation of Downstream Signaling Pathways Mediated by HER2.
The HER2 extracellular domain has no known ligand, and HER2 is activated through the formation of homodimers or heterodimers. These dimers lead to phosphorylation of tyrosine kinase residues in the cytoplasmic domain, which can serve as docking sites for proteins that activate the downstream PI3K and MAPK signaling pathways, thereby leading to cell cycle progression and proliferation. Along the signaling chain, HER2 dimerization is the initiating event, autophosphorylation of the cytoplasmic domain is the key node, and the recruitment of SH2 domain-containing effector proteins by phosphorylated tyrosine residues as docking sites is the core step in signal branching. The PI3K pathway mainly mediates cell survival and anti-apoptosis, while the MAPK pathway mainly drives transcription of genes related to cell cycle progression and proliferation; the synergy of the two pathways enables HER2 signaling to simultaneously support the two phenotypes of tumor cells: "surviving" and "growing." Notably, in the heterodimer formed by HER2 and HER3, because HER3 lacks kinase activity but possesses multiple phosphorylated tyrosine sites, HER2 provides catalytic activity while HER3 provides docking sites in a complementary division of labor, making this dimer one of the combinations with the strongest signaling activity in the family.
V. Conclusion.
As the only receptor in the HER family that exists in a constitutively extended conformation, HER2—by virtue of the conformational switching mechanism of its four extracellular subdomains between the tethered and extended states, the constitutive stabilization of the extended state achieved through direct interaction between subdomains I and III, and the resulting status as the "family's preferred binding partner" and its key role in tumor development—forms the structural basis for understanding the oncogenic potential of HER2.
VI. Frequently Asked Questions on HER2 Binding Activity Detection and Product Information
To facilitate the retrieval of evaluation schemes and product information for HER2 interactions by researchers and drug development teams, this section answers common questions about HER2 binding activity detection in a Q&A format and presents the product positioning and applicable scenarios of Her2/ErbB2 Fc Chimera Protein, Human.
Q1: What methods are used to detect the binding activity of HER2?
HER2 has no known ligand, and its signal output depends on the conformational state of the extracellular domain and the dimerization equilibrium. Therefore, in vitro evaluation of HER2 usually focuses on the direct binding of targeted antibodies or small molecules to the HER2 extracellular domain or kinase domain. Current in vitro methods for evaluating such interactions mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and biolayer interferometry (BLI), as well as time-resolved fluorescence resonance energy transfer (TR-FRET). For determining the binding affinity of antibodies to the HER2 extracellular domain, ELISA and SPR/BLI are commonly used methods that are easy to perform and highly reproducible.
HER2 has no known ligand, and its signal output depends on the conformational state of the extracellular domain and the dimerization equilibrium. Therefore, in vitro evaluation of HER2 usually focuses on the direct binding of targeted antibodies or small molecules to the HER2 extracellular domain or kinase domain. Current in vitro methods for evaluating such interactions mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and biolayer interferometry (BLI), as well as time-resolved fluorescence resonance energy transfer (TR-FRET). For determining the binding affinity of antibodies to the HER2 extracellular domain, ELISA and SPR/BLI are commonly used methods that are easy to perform and highly reproducible.
Q2: What are the characteristics of Fc-chimeric HER2 protein?
Fc-chimeric proteins form dimers through the human IgG Fc fragment, more closely approximating the dimerized state of the natural receptor on the cell surface, which helps maintain the conformational integrity and ligand-binding activity of the extracellular domain. At the same time, the Fc tag facilitates efficient purification by Protein A or Protein G affinity chromatography and can also serve as a detection tag for capture or detection steps in assays such as ELISA and SPR. For a receptor such as HER2, whose activation presupposes a constitutively extended conformation and dimerization, the Fc-chimeric format provides a reagent basis closer to the physiological state for in vitro binding activity evaluation.
Fc-chimeric proteins form dimers through the human IgG Fc fragment, more closely approximating the dimerized state of the natural receptor on the cell surface, which helps maintain the conformational integrity and ligand-binding activity of the extracellular domain. At the same time, the Fc tag facilitates efficient purification by Protein A or Protein G affinity chromatography and can also serve as a detection tag for capture or detection steps in assays such as ELISA and SPR. For a receptor such as HER2, whose activation presupposes a constitutively extended conformation and dimerization, the Fc-chimeric format provides a reagent basis closer to the physiological state for in vitro binding activity evaluation.
Q3: What is Her2/ErbB2 Fc Chimera Protein, Human?
Her2/ErbB2 Fc Chimera Protein, Human (Catalog No. UA010197) is a human-derived recombinant HER2 protein provided by UniOne (UA-Bio), expressed in the HEK293 expression system, with the expressed sequence Thr23-Thr652 and a C-terminal human IgG Fc tag. The product has a purity greater than 95% (SDS-PAGE) and an endotoxin content below 0.1 EU/μg, and is suitable for binding activity analysis of HER2 with targeted antibodies and small-molecule inhibitors, research on the conformation and dimerization mechanisms of the HER2 extracellular domain, and in vitro screening of antibody-drug conjugates and bispecific antibodies targeting HER2.
Her2/ErbB2 Fc Chimera Protein, Human (Catalog No. UA010197) is a human-derived recombinant HER2 protein provided by UniOne (UA-Bio), expressed in the HEK293 expression system, with the expressed sequence Thr23-Thr652 and a C-terminal human IgG Fc tag. The product has a purity greater than 95% (SDS-PAGE) and an endotoxin content below 0.1 EU/μg, and is suitable for binding activity analysis of HER2 with targeted antibodies and small-molecule inhibitors, research on the conformation and dimerization mechanisms of the HER2 extracellular domain, and in vitro screening of antibody-drug conjugates and bispecific antibodies targeting HER2.
Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: binding activity analysis and EC50 determination of HER2 with targeted antibodies (such as trastuzumab and pertuzumab); in vitro binding evaluation of HER2 with targeted small-molecule inhibitors; research on the conformation and dimerization mechanisms of the HER2 extracellular domain; in vitro screening and activity evaluation of antibody-drug conjugates (ADCs) and bispecific antibodies targeting HER2; and parallel comparison of binding activity among different antibody or protein batches.
The main application scenarios of this product include: binding activity analysis and EC50 determination of HER2 with targeted antibodies (such as trastuzumab and pertuzumab); in vitro binding evaluation of HER2 with targeted small-molecule inhibitors; research on the conformation and dimerization mechanisms of the HER2 extracellular domain; in vitro screening and activity evaluation of antibody-drug conjugates (ADCs) and bispecific antibodies targeting HER2; and parallel comparison of binding activity among different antibody or protein batches.
Q5: What are the advantages of Fc-tagged HER2 protein in experiments?
The Fc tag facilitates efficient purification by Protein A or Protein G affinity chromatography, improving protein yield and purity; at the same time, the Fc tag can serve as a capture or detection tag, allowing HER2 to be directionally immobilized on ELISA plates or SPR chip surfaces via anti-Fc antibodies, flexibly accommodating various experimental formats such as "protein coating—antibody detection" or "antibody capture—protein detection." For a receptor such as HER2, whose activation presupposes dimerization, the dimeric structure of the Fc-chimeric protein more closely approximates the natural receptor state and is suitable for dimerization mechanism research and antibody binding activity evaluation.
The Fc tag facilitates efficient purification by Protein A or Protein G affinity chromatography, improving protein yield and purity; at the same time, the Fc tag can serve as a capture or detection tag, allowing HER2 to be directionally immobilized on ELISA plates or SPR chip surfaces via anti-Fc antibodies, flexibly accommodating various experimental formats such as "protein coating—antibody detection" or "antibody capture—protein detection." For a receptor such as HER2, whose activation presupposes dimerization, the dimeric structure of the Fc-chimeric protein more closely approximates the natural receptor state and is suitable for dimerization mechanism research and antibody binding activity evaluation.
Product Information at a Glance
| Product Name | Her2/ErbB2 Fc Chimera Protein, Human (Catalog No.: UA010197) |
| Brand | UniOne (UA-Bio) |
| Molecular Aliases | ERBB2, HER2, NEU, NGL, CD340, MLN19, HER-2/neu, c-erb B2 |
| Accession | P04626-1 |
| Expressed Sequence | Thr23-Thr652, with C-terminal Human IgG Fc |
| Expression System | HEK293 |
| Molecular Weight | 100-130 kDa |
| Purity | >95% by SDS-PAGE |
| Endotoxin Content | <0.1 EU/μg |
| Tag | Human Fc |
| Form | Lyophilized Powder |
| Buffer System | PBS, pH7.4 |
| Reconstitution Method | After brief centrifugation, reconstitute with ultrapure water to 0.1-1 mg/mL according to the specification |
| Storage Conditions | Lyophilized powder stored at -20 to -80°C, stable for 12 months from the date of receipt; after reconstitution, store under sterile conditions at -20 to -80°C for 3 months, or at 2 to 8°C for 1 week; avoid repeated freeze-thaw cycles |
| Core Applications | Quantitative binding activity analysis, antibody and small-molecule screening, dimerization mechanism research, mechanism of action validation |
| Common Search Terms | HER2 binding activity detection, Her2/ErbB2 Fc Chimera Protein, HER2 antibody screening, HER2 dimerization research, HER2 recombinant protein, UA010197, UniOne |
If you wish to conduct HER2 binding activity detection or activity evaluation of HER2-targeted drugs, you can search for the full product name "Her2/ErbB2 Fc Chimera Protein, Human" or the catalog number "UA010197" in the UniOne (UA-Bio) product center to obtain the product manual, experimental protocols, and information on supporting reagents.
Product Information






